Melanoma Dispatch
Follow
Find tag "gp100"
2.4K views | +0 today
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Suggested by Cancer Commons
Scoop.it!

New Melanoma Immunotherapy Advances in Early Trials

New Melanoma Immunotherapy Advances in Early Trials | Melanoma Dispatch | Scoop.it

On the strength of a promising phase I clinical trial, evaluations are continuing for an experimental immunotherapy that targets and selectively kills melanoma cells. Called IMCgp100, the drug has two parts that are fused together. One part is an immune system protein that has been engineered to recognize a protein called gp100, which is on the surface of melanoma cells. The other part of the new drug is a protein fragment that boosts the immune response against the tumor. The phase II trial of IMCgp100 is currently recruiting new participants.

Cancer Commons's insight:

Immunocore Limited│Oct 31, 2013

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

German Health Institute Says Ipilimumab Benefits Melanoma Patients

Melanoma patients live longer when treated with ipilimumab than with an experimental tumor vaccine called gp100, according to a study by the German Institute for Quality and Efficiency in Health Care. People treated with ipilimumab lived 10 months, while those who were not lived 6.5 months. In addition, ipilimumab did not make people’s quality of life worse. People had the same symptoms—nausea, vomiting, digestive disorders, fatigue, and pain—whether they were treated with the drug or with a placebo.

 

Primary source: https://www.iqwig.de/considerable-added-benefit-of-ipilimumab-in.1454.en.html?random=b17062

Cancer Commons's insight:

Doctor Tipster | Nov 9, 2012

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

New Combination Vaccine for Melanoma Enters Early Clinical Trial

New Combination Vaccine for Melanoma Enters Early Clinical Trial | Melanoma Dispatch | Scoop.it

A new clinical trial is underway for an immune system booster that makes an experimental vaccine against melanomas work better. The experimental vaccine is gp100, a protein made by melanoma cells, and the immune system booster is a heat shock protein. The latter got its name because it protects other proteins from heat and other forms of stress, but heat shock proteins also stimulate the immune response. The phase I trial of this combination vaccine will include 12 to 20 people with melanomas that have spread, and is currently recruiting participants.

Cancer Commons's insight:

Roswell Park Cancer Institute│Jun 28, 2013

more...
No comment yet.